Xaliproden (BioDeep_00000185026)

   

human metabolite blood metabolite


代谢物信息卡片


1-(2-(Naphth-2-yl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,5,6-tetrahydropyridine hydrochloride

化学式: C24H22F3N (381.1704)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CN(CC=C1C2=CC(=CC=C2)C(F)(F)F)CCC3=CC4=CC=CC=C4C=C3
InChI: InChI=1S/C24H22F3N/c25-24(26,27)23-7-3-6-22(17-23)20-11-14-28(15-12-20)13-10-18-8-9-19-4-1-2-5-21(19)16-18/h1-9,11,16-17H,10,12-15H2

描述信息

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists
C26170 - Protective Agent > C1509 - Neuroprotective Agent
N - Nervous system

同义名列表

10 个代谢物同义名

1-(2-(Naphth-2-yl)ethyl)-4-(3-trifluoromethylphenyl)-1,2,5,6-tetrahydropyridine hydrochloride; 1-(2-(Naphth-2-yl)ethyl)-4-(trifluoromethylphenyl)-1,2,5,6-tetrahydropyridine hydrochloride; 1,2,3,6-Tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(alpha,alpha,alpha-trifluoro-m-tolyl)pyridine; 1-[2-(naphthalen-2-yl)ethyl]-4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine; 1,2,3,6-Tetrahydro-1-(2-(2-naphthalenyl)ethyl)-4-(3-(trifluoromethyl)phenyl)-pyridine; 1,2,3,6-Tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(a,a,a-trifluoro-m-tolyl)pyridine; 1,2,3,6-Tetrahydro-1-(2-(2-naphthyl)ethyl)-4-(α,α,α-trifluoro-m-tolyl)pyridine; Xaliproden hydrochloride; Xaliproden; SR 57746



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • Ammar Al-Chalabi, Pamela J Shaw, Carolyn A Young, Karen E Morrison, Caroline Murphy, Marie Thornhill, Joanna Kelly, I Nicholas Steen, P Nigel Leigh. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31]. BMC neurology. 2011 Sep; 11(?):111. doi: 10.1186/1471-2377-11-111. [PMID: 21936930]
  • J Fournier, G Boutot, P E Keane, J P Maffrand, G Le Fur, P Soubrié. The non-peptide neuroprotective agents SR 57746A interacts with neurotrophin 3 to induce differentiation in the PC12 cell-line. The Journal of pharmacy and pharmacology. 1998 Mar; 50(3):323-7. doi: 10.1111/j.2042-7158.1998.tb06868.x. [PMID: 9600726]
  • M Magazin, P Schiltz, J L Zachayus, E Cavrois, D Caput, P Ferrara. Inhibition of lysophosphatidic acid-induced neurite retraction and cell rounding by SR 57746A. Brain research. Molecular brain research. 1998 Jan; 53(1-2):301-6. doi: 10.1016/s0169-328x(97)00299-4. [PMID: 9473704]
  • A Pradines, M Magazin, P Schiltz, G Le Fur, D Caput, P Ferrara. Evidence for nerve growth factor-potentiating activities of the nonpeptidic compound SR 57746A in PC12 cells. Journal of neurochemistry. 1995 May; 64(5):1954-64. doi: 10.1046/j.1471-4159.1995.64051954.x. [PMID: 7722483]
  • T Croci, M Landi, A Bianchetti, L Manara. Drug-induced defaecation in rats: role of central 5-HT1A receptors. British journal of pharmacology. 1995 May; 115(1):203-9. doi: 10.1111/j.1476-5381.1995.tb16340.x. [PMID: 7647978]